logo
  Join        Login             Stock Quote

PDL Biopharma (PDLI) 4Q Earnings Jump 27 Pct, Top Estimates

 March 01, 2013 04:22 PM
 


(By Balaseshan) PDL BioPharma Inc. (NASDAQ: PDLI) reported a 27% jump in quarterly earnings on higher royalties from Herceptin and Avastin sales. Earnings exceeded Wall Street expectations.

Earnings for the fourth quarter were $49.41 million or $0.34 per share, up from $38.94 million or $0.24 per share in the previous year quarter.

Total revenue increased 18.2% to $86.05 million, primarily driven by increased royalties from third quarter 2012 sales of Herceptin and Avastin, which are marketed by Genentech and Roche.

Analysts, on average, polled by Thomson Reuters had expected a profit of $0.32 per share on revenue of $86.08 million for the fourth quarter.

[Related -Jobs Growth Tepid At Best]

Royalty revenues for the fourth quarter of 2012 are based on third quarter product sales by PDL's licensees. Royalty revenue for the fourth quarter are net of payments made under its February 2011 settlement agreement with Novartis Pharma AG (NYSE: NVS).

Net cash provided by operating activities in 2012 was $210.2 million, compared with $169.8 million in 2011.

At December 31, 2012, PDL had cash, cash equivalents and investments of $148.7 million, compared with $227.9 million at December 31, 2011.

PDLI closed Friday's regular session down 0.57% at $6.95. The stock has been trading between $6.02 and $8.43 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageFour Stocks in the Dow Making Fresh 52 Week Lows

“What gets weak tends to get weaker; what gets strong tends to get read on...

article imageGreece And The Cemetery For Your Wealth

The Greek default is merely the opening act of the worst sovereign-debt crisis in history. By the time it read on...

article imageAll Signs Point To Higher Gold Prices

In the face of historic monetary stimulus from nearly every major central bank in the world over the past read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.